Venus Remedies has received product patent grant from Indian Patent Office (IPO) for its unique research product, Vancoplus. It is valid till 2025. Vancoplus is a novel antibiotic adjuvant entity highly effective against notorious (MRSA) strain and multi-drug resistant microbes primarily responsible for causing infections such as Meningitis, Pneumonia, Typhoid, Septicemia, Urinary Tract Infection, Skin infections and Staphylococcal Endocarditis. It is also active against different mechanisms of resistance such as cell membrane impermeability, efflux pumps, biofilms, which no other existing therapeutic options available in the market are able to address.
It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product. It is one the best and safest option to address MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens. The total market size of MRSA in the world accounts for $ 9 billion. At present, it is growing with CAGR of 4.8 per cent which is estimated to reach to 12.4 per cent by 2017. In India, Vancoplus would have an addressable market of Rs. 214 crore by 2018-19.
Vancoplus has already been launched in the Indian market and till date approx 80,000 patients have been cured with it. It has received an overwhelming response from the medical fraternity in India. The company has conducted clinical trials on large patient population to prove the clinical efficacy and safety, which is further validated by publications in peer reviewed journals. Venus has more than 15 papers on this product.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: